GlassScriptPhysician profile
Laura Greyling
NPI 1255620233
$8,244.08
in general payments reported to CMS, 2019-2025
31 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,296 · 2020: $678 · 2021: $921 · 2022: $1,673 · 2023: $1,174 · 2024: $1,167 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,591 · Education: $85.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,590.78 |
| Education | $85.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,303.36 | 2019-2025 | Dupixent, Libtayo |
| Abbvie INC. | $928.99 | 2019-2025 | |
| Genzyme Corporation | $727.63 | 2019-2025 | |
| Lilly USA, LLC | $528.42 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $496.46 | 2019-2025 | |
| Leo Pharma INC. | $478.06 | 2019-2025 | Adbry |
| Amgen INC. | $476.77 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $359.56 | 2021-2024 | Opzelura |
| Pfizer INC. | $287.55 | 2019-2025 | |
| Janssen Biotech, INC. | $227.32 | 2020-2023 | Simponi, Stelara, Remicade |
| Almirall LLC | $191.75 | 2019-2025 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $182.54 | 2022-2024 | Sotyktu |
| Ucb, INC. | $125.50 | 2022-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $124.29 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $121.15 | 2023-2024 | Winlevi, Absorica Ld |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $103.54 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $79.41 | 2019-2020 | |
| Celgene Corporation | $67.08 | 2019 | |
| Prugen, INC. Pharmaceuticals | $59.55 | 2019 | |
| Boston Scientific Corporation | $56.85 | 2022 | |
| Vyne Pharmaceuticals INC. | $44.32 | 2020 | |
| Musculoskeletal Transplant Foundation INC. | $44.30 | 2022 | |
| Dermira, INC. | $40.61 | 2020 | |
| Allergan, INC. | $40.53 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $36.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.35 | 2024 | Spevigo |
| Merck Sharp & Dohme LLC | $19.35 | 2019 | |
| Mylan Pharmaceuticals INC. | $18.71 | 2019 | |
| Biofrontera INC. | $17.79 | 2025 | Ameluz |
| Journey Medical Corporation | $17.70 | 2023 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Greyling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.